Henry D Reyes1, Matthew J Carlson2, Eric J Devor3, Yuping Zhang4, Kristina W Thiel5, Megan I Samuelson6, Megan McDonald7, Shujie Yang8, Jean-Marie Stephan9, Erica C Savage10, Donghai Dai11, Michael J Goodheart12, Kimberly K Leslie13. 1. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: henry-reyes@uiowa.edu. 2. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Matthew.Carlson@utsouthwestern.edu. 3. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: eric-devor@uiowa.edu. 4. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Yuping-zhang@uiowa.edu. 5. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Kristina-thiel@uiowa.edu. 6. Department of Pathology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: megan-samuelson@uiowa.edu. 7. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: megan-e-mcdonald@uiowa.edu. 8. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA; Department of Pathology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Shujie-yang@uiowa.edu. 9. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: jean-marie-stephan@uiowa.edu. 10. Department of Pathology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: savagee2@ccf.org. 11. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Donghai-dai@uiowa.edu. 12. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Michael-goodheart@uiowa.edu. 13. Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address: Kimbery-Leslie@uiowa.edu.
Abstract
OBJECTIVE: To examine hormone receptor expression levels and downstream gene activation in pre-treatment and post-treatment biopsies in a cohort of patients with endometrial pathology who were being conservatively managed with a progestin-containing intrauterine device (IUD). A molecular signature of treatment failure is proposed. METHODS: A retrospective analysis of pre- and post-treatment biopsy specimens from 10 women treated with progestin-containing IUD for complex atypical hyperplasia (CAH) or grade 1 endometrioid adenocarcinoma was performed. Expression of estrogen receptor (ER), progesterone receptor (PR) and PR target genes was examined by immunohistochemistry (IHC) and quantitative RT-PCR. RESULTS: The mean treatment duration was 14.3 months. Four CAH patients had stable disease or regressed after treatment, and four progressed to endometrioid adenocarcinoma. Both patients with an initial diagnosis of endometrioid adenocarcinoma regressed to CAH or no disease. In general, hormone receptor levels diminished post-treatment compared to pre-treatment biopsies; however, we noted unexpected higher expression of the B isoform of PR (PRB) as well as ER in those patients who progressed to frank cancer. There was a trend towards a non-nuclear cytoplasmic location of PRB in these patients. Importantly, the differentiating impact of PR signaling, as determined by the expression of the progestin-controlled tumor suppressor FOXO1, was lost in individuals who progressed on therapy. CONCLUSIONS: FOXO1 mRNA levels may serve as a biomarker for response to therapy and an indicator of PR function in patients being conservatively managed with a progestin-containing IUD.
OBJECTIVE: To examine hormone receptor expression levels and downstream gene activation in pre-treatment and post-treatment biopsies in a cohort of patients with endometrial pathology who were being conservatively managed with a progestin-containing intrauterine device (IUD). A molecular signature of treatment failure is proposed. METHODS: A retrospective analysis of pre- and post-treatment biopsy specimens from 10 women treated with progestin-containing IUD for complex atypical hyperplasia (CAH) or grade 1 endometrioid adenocarcinoma was performed. Expression of estrogen receptor (ER), progesterone receptor (PR) and PR target genes was examined by immunohistochemistry (IHC) and quantitative RT-PCR. RESULTS: The mean treatment duration was 14.3 months. Four CAH patients had stable disease or regressed after treatment, and four progressed to endometrioid adenocarcinoma. Both patients with an initial diagnosis of endometrioid adenocarcinoma regressed to CAH or no disease. In general, hormone receptor levels diminished post-treatment compared to pre-treatment biopsies; however, we noted unexpected higher expression of the B isoform of PR (PRB) as well as ER in those patients who progressed to frank cancer. There was a trend towards a non-nuclear cytoplasmic location of PRB in these patients. Importantly, the differentiating impact of PR signaling, as determined by the expression of the progestin-controlled tumor suppressor FOXO1, was lost in individuals who progressed on therapy. CONCLUSIONS:FOXO1 mRNA levels may serve as a biomarker for response to therapy and an indicator of PR function in patients being conservatively managed with a progestin-containing IUD.
Authors: L A Brinton; M L Berman; R Mortel; L B Twiggs; R J Barrett; G D Wilbanks; L Lannom; R N Hoover Journal: Am J Obstet Gynecol Date: 1992-11 Impact factor: 8.661
Authors: T Kaku; H Yoshikawa; H Tsuda; A Sakamoto; M Fukunaga; Y Kuwabara; M Hataeg; S Kodama; K Kuzuya; S Sato; T Nishimura; M Hiura; H Nakano; T Iwasaka; K Miyazaki; T Kamura Journal: Cancer Lett Date: 2001-06-10 Impact factor: 8.679
Authors: Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-01-20 Impact factor: 5.482
Authors: Shujie Yang; Yichen Jia; Xiaoyue Liu; Christopher Winters; Xinjun Wang; Yuping Zhang; Eric J Devor; Adriann M Hovey; Henry D Reyes; Xue Xiao; Yang Xu; Donghai Dai; Xiangbing Meng; Kristina W Thiel; Frederick E Domann; Kimberly K Leslie Journal: Oncotarget Date: 2014-10-30
Authors: Pierluigi Giampaolino; Valeria Cafasso; Dominga Boccia; Mario Ascione; Antonio Mercorio; Francesco Viciglione; Mario Palumbo; Paolo Serafino; Cira Buonfantino; Maria Chiara De Angelis; Paolo Verrazzo; Giovanna Grasso; Giuseppe Gullo; Giuseppe Bifulco; Luigi Della Corte Journal: Biomed Res Int Date: 2022-09-27 Impact factor: 3.246